🔎 Trials Near Me

Akèy › Sakom Ewing › Colorado › Aurora

Etid klinik pou Sakom Ewing nan Aurora, CO

6 etid pou Sakom Ewing ap chèche patisipan nan sit nan ak bò kote Aurora (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Ap rekriteFaz 1/2
  • Children's Hospital Colorado-Center for Cancer and Blood Disorders ( Site 1016), Aurora
6 Months – 25 Years · Tout sèks · Mizajou Sep 17, 2026 · NCT06395103

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Ap rekriteFaz 1
  • University of Colorado Hospital, Aurora
Laj 12 a 85 · Tout sèks · Mizajou Sep 8, 2026 · NCT03715933

Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas

Ap rekriteFaz 1
  • Children's Hospital Colorado, Aurora
Laj 5 a 40 · Tout sèks · Mizajou Sep 3, 2026 · NCT06156410

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Ap rekriteFaz 1/2
  • Children's Hospital Colorado, Aurora
12 Months – 30 Years · Tout sèks · Mizajou Aug 25, 2026 · NCT04851119

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

Ap rekriteFaz 1/2
  • Children's Hospital Colorado, Aurora
12 Months – 30 Years · Tout sèks · Mizajou May 19, 2026 · NCT04901702

A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

Ap rekriteFaz 2
  • Children's Hospital of Colorado, Aurora
18 Months – 40 Years · Tout sèks · Mizajou Aug 12, 2025 · NCT05135975

Etid Sakom Ewing nan lòt vil

Lòt etid nan Aurora

Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.